[Comment] COVID‑19 vaccine safety
- Ronald N. Kostoff
- Michael B. Briggs
- Alan L. Porter
- Demetrios A. Spandidos
- Aristidis Tsatsakis
Affiliations: School of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155, USA, Independent Consultant, Roscommon, MI 48653, USA, School of Public Policy, Georgia Institute of Technology, Atlanta, GA 30332, USA, Laboratory of Clinical Virology, Medical School, University of Crete, 70013 Heraklion, Greece, Laboratory of Toxicology, Medical School, University of Crete, 70013 Heraklion, Greece
- Published online on: September 18, 2020 https://doi.org/10.3892/ijmm.2020.4733
Copyright: © Kostoff
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
In response to the SARS‑CoV‑2 outbreak, and the resulting COVID‑19 pandemic, a global competition to develop an anti‑COVID‑19 vaccine has ensued. The targeted time frame for initial vaccine deployment is late 2020. The present article examines whether short‑term, mid‑term, and long‑term vaccine safety can be achieved under such an accelerated schedule, given the myriad vaccine‑induced mechanisms that have demonstrated adverse effects based on previous clinical trials and laboratory research. It presents scientific evidence of potential pitfalls associated with eliminating critical phase II and III clinical trials, and concludes that there is no substitute currently available for long‑term human clinical trials to ensure long‑term human safety.